Image_3_Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment.pdf (863.04 kB)
Download file

Image_3_Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment.pdf

Download (863.04 kB)
figure
posted on 12.01.2022, 04:31 authored by André F. Rendeiro, Charles Kyriakos Vorkas, Jan Krumsiek, Harjot K. Singh, Shashi N. Kapadia, Luca Vincenzo Cappelli, Maria Teresa Cacciapuoti, Giorgio Inghirami, Olivier Elemento, Mirella Salvatore

Deep understanding of the SARS-CoV-2 effects on host molecular pathways is paramount for the discovery of early biomarkers of outcome of coronavirus disease 2019 (COVID-19) and the identification of novel therapeutic targets. In that light, we generated metabolomic data from COVID-19 patient blood using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. We find considerable changes in serum metabolome composition of COVID-19 patients associated with disease severity, and response to tocilizumab treatment. We built a clinically annotated, biologically-interpretable space for precise time-resolved disease monitoring and characterize the temporal dynamics of metabolomic change along the clinical course of COVID-19 patients and in response to therapy. Finally, we leverage joint immuno-metabolic measurements to provide a novel approach for patient stratification and early prediction of severe disease. Our results show that high-dimensional metabolomic and joint immune-metabolic readouts provide rich information content for elucidation of the host’s response to infection and empower discovery of novel metabolic-driven therapies, as well as precise and efficient clinical action.

History

References